XENE
Xenon Pharmaceuticals Inc.
38.34
USD
This page is just a preview of the data found in TrendSpider’s full version
Xenon Pharmaceuticals Inc. stock is up 32.99% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 27 Nov 19:29 | 15 Dec, 2023 | 30.00 | 3404 | ||
| 28 Nov 16:32 | 19 Jan, 2024 | 35.00 | 1316 | ||
| 28 Nov 18:09 | 19 Jan, 2024 | 35.00 | 1316 | ||
| 01 Dec 15:16 | 19 Apr, 2024 | 45.00 | 0 | ||
| 04 Dec 17:25 | 19 Apr, 2024 | 45.00 | 1000 | ||
| 06 Dec 14:49 | 19 Jan, 2024 | 35.00 | 87 | ||
| 06 Dec 15:12 | 19 Apr, 2024 | 45.00 | 2000 | ||
| 06 Dec 15:48 | 15 Dec, 2023 | 30.00 | 1171 | ||
| 07 Dec 14:31 | 15 Dec, 2023 | 30.00 | 1171 | ||
| 08 Dec 16:15 | 15 Dec, 2023 | 40.00 | 4208 |
Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.
